Commentary: C-reactive protein and risk prediction - Moving beyond associations to assessing predictive utility and clinical usefulness

International Journal of Epidemiology

Volumn 38, Issue 1, 2009, Pages 231-234

  Vasan, Ramachandran S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PLACEBO; ROSUVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY RISK; FAMILY HISTORY; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; NOTE; PREDICTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 60149094006     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyn353     Document Type: Note

References (15)

1. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: Conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002;31 285-93.
2. Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006; 113:2335-62.
3. Kuller L, Borhani N, Furberg C et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study. Am J Epidemiol 1994; 139:1164-79.
4. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and hiEh-risk plaque: Part I: evolving concepts. J Am Coll Cardiol 2005;46:937-54.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 2003;107:499-511.
7. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new biomarkers and predictive models for use in clinical practice: A clinician's guide. Arch Intern Med 2008;168:2304-10.
8. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
9. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35.
10. Shah T, Casas JP, Cooper JA et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: New data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38:21731.
11. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The reynolds risk score for men. Circulation 2008;118:2243-51.
12. Wilson PWF, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham heart study. Circ Cardiovasc Qual Outcomes 2008; 1:92-97.
13. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359: 2195-207.
14. Hlatky MA. Expanding the orbit of primary prevention - moving beyond JUPITER. N Engl J Med 2008;359: 2280-82.
15. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.